(Tiper Stock Exchange) – Eli Lillya US pharmaceutical giant listed on the NYSE, has signed a definitive agreement for the acquisition of Versanis Bio, a privately held clinical-stage biopharmaceutical company focused on the development of new drugs for the treatment of cardiometabolic diseases. Versanis’ main drug, the bimagrumabis being evaluated in an interim study by itself and in combination with Novo Nordisk’s Wegovy in the US overweight or obese adults.
“Lilly is busy studying potential new drugs to fight cardiometabolic diseases, including obesity, a chronic disease that affects more than 100 million Americans,” said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and research. cardiometabolic at Lilly – By unifying Lilly’s knowledge and expertise in incretin biology with Versanis’ deep understanding of activin biology, we aim to exploit the potential benefits of such combinations for patients“.
Under the terms of the agreement, Versanis shareholders could receive up to $1.925 billion in cash, consisting of an upfront payment and payments following the achievement of certain development and sales milestones. The transaction is subject to customary closing conditions. This transaction will subsequently be reflected in Lilly’s financial results and financial guidance.